Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal

November 25, 2019 sandiegobiotech News Comments Off on Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
/

SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the ?Company?), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the issued and outstanding shares of the Company for between $3.00 and $5.00 per share in cash.

Related Articles

No Picture
News

Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant

December 28, 2021 sandiegobiotech News Comments Off on Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant

SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the… Click here to view original post… […]

No Picture
News

Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern

August 26, 2021 sandiegobiotech News Comments Off on Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern

SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors… Click here to view original post… […]

No Picture
News

Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

August 19, 2021 sandiegobiotech News Comments Off on Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, released today a preprint publication, which is accessible at: https://www.biorxiv.org/content/10.1101/2021.08.17.456704v1.full.pdf. The publication details preclinical vaccination… Click here to view original post… […]